Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
Program Areas: Vaccine Development
Just Biotherapeutics
Just Biotherapeutics is developing an integrated technology platform to accelerate the development and manufacturing of high-quality biologics at a significantly lower cost, to broaden global biologic access.
Press Release: Kymab secures US $100 million Series C funding
Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More
STAT: Smart strategies and collaboration can help improve global health
By Natalie Revelle October 27, 2016 In 2010 at the Bill & Melinda Gates Foundation, Natalie Revelle was a relatively new financial manager supporting the global health team. Bill Gates was present at a meeting, where Gavi, the global alliance Read More
Stanford Social Innovation Review: Making Markets Work for the Poor
The Stanford Social Innovation Review explores how the Bill & Melinda Gates Foundation uses strategic investments for social impact. Read the full report here. Chapters: Philanthropy’s New Tools for Innovation and Impact Leveraging the Balance Sheet Neglected No More Unintended Read More